Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-15

Study Completion Date

2020-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatorenal syndrome is a functional renal impairment occurring in cirrhotic patients . It develops secondary to splanchnic arterial vasodilatation which decreases the effective blood volume, activate the renin-angiotensin-aldosterone system, and stimulate of sympathetic nervous system.This study aims to compare the efficacy of nor-epinephrine versus midodrine/ octreotide, together with intravenous albumin on renal functions of patients with hepatorenal acute kidney injury.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure

NCT02573727

Acute on Chronic Liver Failure

COMPLETED NA

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

NCT00742339

Cirrhosis Hepatorenal Syndrome

TERMINATED PHASE2/PHASE3

A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center

NCT06095440

Hepatorenal Syndrome

RECRUITING

Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1

NCT03822091

Type 1 HEPATO RENAL SYNDROME(HRS)

COMPLETED PHASE3

RAI & HRS: Relationship Between Relative Adrenal Insufficiency and Failure of Treatment in Hepatorenal Syndrome

NCT04273750

Liver Cirrhosis Acute Kidney Injury Hepato-Renal Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepato-Renal Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Midodrine/Octreotide

oral midodrine plus octreotide as subcutaneous injection

Group Type EXPERIMENTAL

Midodrine/Octreotide

Intervention Type DRUG

oral midodrine plus octreotide as subcutaneous injection

Nor-epinephrine

Intravenous infusion norepinephrine

Group Type ACTIVE_COMPARATOR

Nor-epinephrine

Intervention Type DRUG

Intravenous infusion norepinephrine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Midodrine/Octreotide

oral midodrine plus octreotide as subcutaneous injection

Intervention Type DRUG

Nor-epinephrine

Intravenous infusion norepinephrine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

albumin at doses of 20 to 40 g/day albumin at doses of 20 to 40 g/day

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Both sexes aged 18 years or older having cirrhosis, ascites, and a diagnosis of HRS-AKI based on the 2015 International Club of Ascites (ICA) diagnostic criteria

Exclusion Criteria

Serum creatinine (sCr) \>7 mg/dL Hypotension (mean arterial pressure (MAP) \<70 mm Hg) or sepsis. Recent treatment with vasopressors. Patients with severe cardiovascular disease Known allergy to study medications

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No